BCR gene disruption in a pilomyxoid astrocytoma

Neuropathology

Volumn 26, Issue 5, 2006, Pages 442-446

  Meléndez, Bárbara ^a   Fiaño, Concepción ^b   Ruano, Yolanda ^a   Hernández Moneo, Jose L ^a   Mollejo, Manuela ^a   Martinez, Pedro ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

Author keywords

BCR gene; Imatinib; Insertion on chromosome 17; Pilomyxoid astrocytoma; Tyrosine kinase proteins

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; ASTROCYTOMA; CASE REPORT; CHROMOSOME 17; CHROMOSOME ANALYSIS; CHROMOSOME INSERTION; CRANIOTOMY; DIENCEPHALON; GENE DISRUPTION; GENE REARRANGEMENT; GLIOMA; HEMISPHERE; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; ONCOGENE; PILOMYXOID ASTROCYTOMA; PRIORITY JOURNAL;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 22; FATAL OUTCOME; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MAGNETIC RESONANCE IMAGING; MALE; PROTO-ONCOGENE PROTEINS C-BCR;

EID: 33749019092     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2006.00712.x     Document Type: Article

References (16)

1. Burger PC, Cohen KJ, Rosenblum MK, Tihan T. Pathology of diencephalic astrocytomas. Pediatr Neurosurg 2000; 32: 214-219.
2. Tihan T, Fisher PG, Kepner JL et al. Paediatric astrocytomas with monomorphous pilomyxoid features and less favourable outcome. J Neuropathol Exp Neurol 1999; 58: 1061-1068.
3. Cenacchi G, Giangaspero F. Emerging tumor entities and variants of CNS variants. J Neuropathol Exp Neurol 2004; 63: 185-192.
4. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 2001; 61: 2343-2355.
5. Garcia JF, Camacho FI, Morente M et al. Spanish Hodgkin Lymphoma Study Group. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101: 681-689.
6. Darling JL. In vitro culture of malignant brain tumors. In: Pfragner R, Freshney RI (eds). Culture of Human Tumor Cells. Culture of specialized cells. Hoboken, New Jersey: Wylley-Liss, 2004; 349-372.
7. Griesinger F, Podleschny M, Steffens R, Bohlander SK, Woermann B, Haase D. A novel BCR-JAK2 fusion gene is the result of a translocation t(9;22)(p24;q11) in a case of CML. Blood 2000; 96: 352a.
8. Baxter EJ, Hochhaus A, Bolufer P et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002; 11: 1391-1397.
9. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. Expression of PDGF and PDGF-receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 1995; 60: 168-173.
10. Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213-3219.
11. McLaughlin ME, Robson CD, Kieran MW, Jacks T, Pomeroy SL, Cameron S. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. Pediatr Hematol Oncol 2003; 25: 644-648.
12. Roggero E, Giancarla B, Antonella P, Augusto P. Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient. J Neurooncol 2005; 71: 277-280.
13. Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 2004; 45: 401-403.
14. Leis JF, Stepan DE, Curtin PT et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004; 45: 695-698.
15. Senior K. Gleevec does not cross blood-brain barrier. Lancet Oncol 2003; 4: 198.
16. Kim MK, Lee KH, Lee JK, Choi JH, Hyun MS. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer 2005; 50: 265-269.